SAN
Santhera
Stock
Stock
ISIN: CH1276028821
Ticker: SANN
CH1276028821
SANN
Price
Price
CHART BY
Frequently asked questions
What is Santhera's market capitalization?
The market capitalization of Santhera is 169.26M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Santhera?
Santhera's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.435. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Santhera's stock?
Currently, 2 analysts cover Santhera's stock, with a consensus target price of 27.00. Analyst ratings provide insights into the stock's expected performance.
What is Santhera's revenue over the trailing twelve months?
Over the trailing twelve months, Santhera reported a revenue of 39.12M.
What is the EBITDA for Santhera?
Santhera's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -27.74M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Santhera?
Santhera has a free cash flow of -35.68M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Santhera have, and what sector and industry does it belong to?
Santhera employs approximately 79 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Santhera's shares?
The free float of Santhera is 10.02M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- 169.26M
- EPS (TTM)
- -$3.435
- Free Float
- 10.02M
- Revenue (TTM)
- 39.12M
- EBITDA (TTM)
- -27.74M
- Free Cashflow (TTM)
- -35.68M
Pricing
- 1D span
- $15.96$16.87
- 52W span
- $8.161$19.65
Analyst Ratings
The price target is 27.00 and the stock is covered by 2 analysts.
Buy
2
Hold
0
Sell
0
Information
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. Its product pipeline includes Vamorolone and Lonodelestat. The company was founded by Thomas Meier in 1998 and is headquartered in Pratteln, Switzerland.
- Employees
- 79
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- CH1276028821
- Primary Ticker
- SANN
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet